StockNews.AI
MRNS
StockNews.AI
20 days

MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigates claims against Marinus Pharmaceuticals (MRNS). 2. Lawsuit alleges misleading statements regarding RAISE trial risks. 3. Claims involve potential fiduciary duty breaches by MRNS board. 4. Class action period spans March 17, 2021, to May 7, 2024. 5. Investors encouraged to discuss legal rights with law firm.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation and lawsuit indicate significant risks and potential losses for investors, reminiscent of historical instances where class actions negatively impacted stock valuations, such as in the case of biotech companies facing trial-related setbacks or fiduciary issues.

How important is it?

The direct involvement of shareholder rights litigation suggests serious implications for MRNS's stock performance due to potential fiduciary breaches, which can severely impact investor confidence and stock price.

Why Short Term?

Immediate investor sentiment is likely to be affected as news spreads, similar to past incidents where class actions led to instant sell-offs or increased volatility in stock prices.

Related Companies

MRNSAXSMHRTXPTGXPULM
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Marinus (MRNS) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Marinus between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) on behalf of long-term stockholders following a class action complaint that was filed against Marinus on June 5, 2024 with a Class Period from March 17, 2021 and May 7, 2024. Our investigation concerns whether the board of directors of Marinus have breached their fiduciary duties to the company. According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. If you are a long-term stockholder of Marinus, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News